多病共存对活动性类风湿关节炎新治疗启动及达标的影响:基于RISE注册的队列研究
该回顾性队列研究利用RISE注册数据,纳入活动性RA患者(RAPID3队列15,626例,CDAI队列5,733例),评估多病共存(RxRisk指数)与新DMARD启动及达标(低疾病活动度或缓解)的关联。结果显示多病共存与新DMARD启动无关,但多病共存负担越高,达标几率越低(RAPID3队列每1单位RxRisk OR 0.95,95%CI 0.91-0.98;CDAI队列OR 0.94,95%CI 0.90-0.99)。
要点
- 多病共存不阻碍活动性RA患者启动新DMARD。
- 多病共存负担越高,RA治疗达标几率越低。
- 最高多病共存负担者达标几率最低(RAPID3队列OR 0.54)。
核心结论
- 多病共存与活动性RA患者新DMARD启动无关,但与较低的治疗达标几率相关。
研究设计与样本
- 回顾性队列研究,使用RISE注册数据,纳入活动性RA成人患者。
- 多病共存采用基于药物的RxRisk指数测量。
- RAPID3队列15,626例,CDAI队列5,733例;其中1,558例(RAPID3)和834例(CDAI)启动新DMARD并有随访疾病活动度测量。
主要发现
- 多病共存与新DMARD启动无关联。
- 每增加1单位RxRisk,达标几率降低:RAPID3队列OR 0.95(95%CI 0.91, 0.98);CDAI队列OR 0.94(95%CI 0.90, 0.99)。
- 最高多病共存负担者达标几率最低:RAPID3队列OR 0.54(95%CI 0.34, 0.85);CDAI队列OR 0.65(95%CI 0.37, 1.15)。
关键数值与推荐
- 多病共存采用RxRisk药物基础指数测量,患者平均涉及6至7个RxRisk类别。
- 达标定义为低疾病活动度或缓解。
- 新DMARD启动为活动性RA中启动新的改善病情抗风湿药。
临床怎么用
- 对多病共存负担高的活动性RA患者,应关注其达标几率可能较低。
- 可能需要针对多病共存采取更整体的管理方法以优化RA疾病控制。
局限性
- 回顾性队列设计。
- 患者以中年、女性、白人为主。
- 多病共存基于药物索引测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether multimorbidity is associated with treatment changes and achieving target disease activity thresholds in patients with active rheumatoid arthritis (RA). METHODS: We conducted a retrospective cohort study of adults with active RA within the Rheumatology Informatics System for Effectiveness (RISE) registry. Multimorbidity was measured using RxRisk, a medication-based index of chronic disease. We used multivariable logistic regression models to assess the associations of multimorbidity with the odds of initiating a new disease-modifying antirheumatic drug (DMARD) in active RA, and among those initiating a new DMARD, the odds of achieving low disease activity or remission. RESULTS: We identified 15,626 patients using the Routine Assessment of Patient Index Data 3 (RAPID3) cohort and 5,733 patients using the Clinical Disease Activity Index (CDAI) cohort. All patients had active RA, of which 1,558 (RAPID3) and 834 (CDAI) initiated a new DMARD and had follow-up disease activity measures. Patients were middle aged, female, and predominantly White, and on average received medications from 6 to 7 RxRisk categories. Multimorbidity was not associated with new DMARD initiation in active RA. However, a greater burden of multimorbidity was associated with lower odds of achieving treatment targets (per 1-unit RxRisk: RAPID3 cohort odds ratio [OR] 0.95 [95% confidence interval (95% CI) 0.91, 0.98]; CDAI cohort OR 0.94 [95% CI 0.90, 0.99]). Those with the highest burden of multimorbidity had the lowest odds of achieving target RA disease activity (RAPID3 cohort OR 0.54 [95% CI 0.34, 0.85]; CDAI cohort OR 0.65 [95% CI 0.37, 1.15]). CONCLUSION: These findings from a large, real-world registry illustrate the potential impact of multimorbidity on treatment response and indicate that a more holistic management approach targeting multimorbidity may be needed to optimize RA disease control in these patients.
引用
- England BR, Yun H, Chen L, et al. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. Arthritis Care Res (Hoboken). 2022. PMID: 34338449. doi:10.1002/acr.24762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。